Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Maria Cronhjort, Rebecka Rubenson Wahlin, Stephan M. Jakob, Luca Cioccari, Maj-Brit Norregaard Kjaer, Gitte Kingo Vesterlund, Tine Sylvest Meyhoff, Marie Helleberg, Morten Hylander Moller, Thomas Benfield, Balasubramanian Venkatesh, Naomi E. Hammond, Sharon Micallef, Abhinav Bassi, Oommen John, Vivekanand JhaKlaus Tjelle Kristiansen, Charlotte Suppli Ulrik, Vibeke Lind Jorgensen, Margit Smitt, Morten H. Bestle, Anne Sofie Andreasen, Lone Musaeus Poulsen, Bodil Steen Rasmussen, Anne Craveiro Brochner, Thomas Strom, Anders Moller, Mohd Saif Khan, Ajay Padmanaban, Jigeeshu Vasishtha Divatia, Sanjith Saseedharan, Kapil Borawake, Farhad Kapadia, Subhal Dixit, Rajesh Chawla, Urvi Shukla, Pravin Amin, Michelle S. Chew, Christian Aage Wamberg, Christian Gluud, Theis Lange, Anders Perner

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageEnglish
JournalIntensive Care Medicine
Volume48
Pages (from-to)45–55
Number of pages11
ISSN0342-4642
DOIs
Publication statusPublished - 2022

Keywords

  • COVID-19
  • Hypoxaemia
  • Critical illness
  • Corticosteroids
  • Bayesian analysis

Cite this